According to last weeks financial statement BMS Beat earning estimates and "Revenue for Eliquis, the anti-coagulant approved in 2013, was $171 million, topping a $129.2 million estimate." This is 135% of Budget. So what was the IC budget qualifier for the reps last year? 135%?
Eliquis did not beat Budget in 2013 I think you're mis-reading the report. The public financials (link below) indicate that it was $171M worldwide in Q2 2014, of which $94M was US. The same line-item shows $5M for Eliquis in Q2 2013. I didn't spot the $129.2M estimate you quote, but last year those early sales were so low BMS invoked a minimum multiplier and paid the CV team far more than if the actual attainment had been used. You weren't cheated, you were actually protected. Then had a lower forecast benchmark. Then were protected again. Reading CafePharma I understand the sales teams have a number of complaints, and I'll trust some may be legitimate. This shouldn't be one of them. BMS tried hard to do right by the CV sales team during launch; those of us who had been in home office had no such protection. Here's the publicly available Q2 '14 report: http://news.bms.com/press-release/financial-news/bristol-myers-squibb-reports-second-quarter-2014-financial-results
Re: Eliquis did not beat Budget in 2013 Your post just proves the point that reps are basically stupid. You actually had to point out to the idiot rep that $171m was world wide sales. Good job, but sad you had to do it.
Question: What are the first words spoken after sex in WV? Answer:"Get off me Daddy, you're mashin' my cigarettes ".....